Search Results
176 items found for "immune response"
- 📰 GPCR Weekly News, March 18 to 24, 2024
GPCR) gene variants and human genetic disease Advances and challenges in cancer immunoprevention and immune
- 📰 GPCR Weekly News, April 1 to 7, 2024
steatotic liver disease GPCRs in Oncology and Immunology Chemoattractant receptor signaling in humoral immunity
- All Aboard the GPCR Express: Your Weekly Update is here! Oct 14-20, 2024
Congrats to: Monserrat Avila-Zozaya , our incredible contributor, for her fantastic article on Profiling Immune
- 📰 GPCR Weekly Buzz: Exciting Schedule Shifts for Principles of Pharmacology I & II | August 12-18, 2024
neurogenic properties GPCRs in Oncology and Immunology Chemoattractant receptor signaling in humoral immunity
- 📰 GPCR Weekly News, August 14 to 20, 2023
exposure on neuroinflammation and amelioration by GPR110 (ADGRF1) activation PAXIP1-AS1 is associated with immune
- 📰 GPCR Weekly News, November 6 to November 12, 2023
November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GPCR signaling contributes to immune
- 📰 GPCR Weekly News, September 25 to October 1, 2023
protein-coupled receptors: A target for microbial metabolites and a mechanistic link to microbiome-immune-brain
- 📰 GPCR Weekly News, October 16 to 22, 2023
study 'identifies two deubiquitinases that regulate GPCR-p38 MAPK signaling and distinct inflammatory responses Sakmar and his team used 'bioluminescence resonance energy transfer to measure cell-surface expression identifies CYLD and USP34 as deubiquitinases that regulate GPCR-p38 MAPK signaling and distinct inflammatory responses oocytes for modelling neurological disease for novel drug discovery Application of bioluminescence resonance manipulation, and potential use of Opn5 and its homologs Industry News The Leading GPCR Company in Immuno-Oncology
- 📰 GPCR Weekly News, January 8 to 14, 2024
of small molecules against cannabinoid 2 receptor (CB2R) Ketone bodies as chemical signals for the immune
- Dopamine activates astrocytes in prefrontal cortex via α1-adrenergic receptors
However, basic physiology of PFC astrocytes, including which neuromodulatory signals they respond to signaling signatures in mouse astrocytes of the PFC and primary sensory cortex, which show differential responsiveness We find that PFC astrocytes express receptors for dopamine but are unresponsive through the Gs/Gi-cAMP
- 📰 GPCR Weekly News, November 20 to 26, 2023
Metabolite Concentrations in Portal Venous Blood as a Possible Mechanism for Microbiota Effects on the Immune
- Lack of Oestrogen Receptor Expression in Breast Cancer Cells Does Not Correlate with Kisspeptin...
We show that both cell lines express KISS1R mRNA and respond to KP-10 by elevating calcium mobilisation Moreover, only BT-20 cells responded to KP-10 by increasing ERK phosphorylation in a β-arrestin-dependent universally true that kisspeptin/KISS1R stimulate migration or pro-metastatic behaviour, as divergent responses
- GPCR Buzz of the Week | Sep 23 - 29, 2024
receptors regulate a wide spectrum of endocrine tumors G protein coupled receptor transcripts in human immune
- 📰 GPCR Weekly News, December 11 to 17, 2023
TIMS-TOF MS) A rapid, tag-free way to purify functional GPCRs tANCHOR fast and cost-effective cell-based immunization
- Nanobodies: New Dimensions in GPCR Signaling Research
Generation, selection and functional expression: Nanobodies can be obtained by immunizing a camelid and
- GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!
signaling mechanisms and heterogeneity of astrocyte reactivity in Alzheimer's disease Identification of immune-related
- 📰 GPCR Weekly News, March 25 to March 31, 2024
Profiling the proximal proteome of the activated μ-opioid receptor Computational modelling of dynamic cAMP responses protein-coupled receptor class C group 5 member A expression on lipopolysaccharide-induced inflammatory response Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology
- Domain Therapeutics Raises $42m Series A Financing
"Published: May 10, 2022 To accelerate clinical development of its best-in-class and first-in-class immuno-oncology in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology
- 📰 GPCR Weekly News, October 30 to November 4, 2023
Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine arrive Form and Function - Consequences of subcellular cAMP signaling revealed AI Predicts How GPCRs Respond
- Glyco-sulfo hotspots in the chemokine receptor system
these PTMs in the chemokine receptor system which may ultimately allow for new precise targeting of the immune
- In vivo detection of GPCR-dependent signaling using fiber photometry and FRET-based biosensors
Many such biosensors are based on the principle of Förster resonance energy transfer (FRET), and we have with FRET-based biosensors, we were able to track GPCR-dependent signaling pathways over time, and in response neuronal populations, we can quantify intracellular signaling while simultaneously measuring behavioral responses After several weeks to allow biosensor expression, fiber photometry is used in order to record drug responses
- Molecular basis for variations in the sensitivity of pathogenic rhodopsin variants to 9-cis-retinal
However, the magnitude of the response to this molecule varies considerably across this spectrum of mutations binding and folding suggests underlying differences in stability constrains the magnitude of their response comprehensive experimental characterization of the proteostatic properties of retinopathy variants and their response
- The complicated lives of GPCRs in cardiac fibroblasts
contractility, whereas stimulation of Gq-coupled receptors modulates cellular survival and hypertrophic responses We also review the hierarchy of signaling events driving the fibrotic response and the communications
- Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery
This dual role opens new possibilities for more complex and nuanced cellular responses. feedback mechanisms and spatial localisation within the cell, is a crucial determinant of cellular responses The choice of pathway can result in different cellular responses, underscoring the criticality of precise immunofluorescence staining, HTRF (homogeneous time-resolved fluorescence), and TR-FRET (time-resolved fluorescence resonance
- An overview of the compartmentalized GPCR Signaling: Relevance and Implications
including endosomes, the Golgi apparatus, and the nuclear membrane, leading to spatially biased signaling responses Showing that this spatially biased signaling through arrestins can influence transcriptional responses cellular processes, including phospholipase C epsilon (PLCε)-dependent signaling and transcriptional responses localized to the nuclear membrane have emerged as important regulators of gene transcription and cellular responses underlying spatial bias in GPCR signaling involve both temporal and spatial components, sustained signaling responses
- Structures of β 1-adrenergic receptor in complex with Gs and ligands of different efficacies
efficacies, and transduce to heterotrimeric G-proteins to generate different degrees of physiological responses studies with mutations of β1-AR residues show effects on the cellular signaling from β1-AR to the cAMP response
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
enabling a more detailed understanding of how genetic variation within human populations affects drug response By evaluating a broad spectrum of mutations, DMS can help predict which patient subpopulations will respond
- GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions
of a ligand on a receptor's structure and biophysical attributes, and consequently on the biological response ligands can be categorized into four distinct efficacy classes: 1) full agonists produce the maximal response agonists), inhibition of activation (e.g., antagonists), or produce an inversion of the functional response